Literature DB >> 32492895

Genotype-Related Clinical Characteristics and Myocardial Fibrosis and their Association with Prognosis in Hypertrophic Cardiomyopathy.

Hyung Yoon Kim1, Jong Eun Park2, Sang-Chol Lee3, Eun-Seok Jeon3, Young Keun On3, Sung Mok Kim4, Yeon Hyeon Choe4, Chang-Seok Ki5, Jong-Won Kim6, Kye Hun Kim1.   

Abstract

BACKGROUND: The spectrum of genetic variants and their clinical significance of Hypertrophic cardiomyopathy (HCM) have been poorly studied in Asian patients. The objectives of this study were to assess the spectrum of genetic variants and genotype-phenotype relationships within a Korean HCM population.
METHODS: Eighty-nine consecutive unrelated HCM patients were included. All patients underwent genotypic analysis for 23 HCM-associated genes. Clinical parameters including echocardiographic and cardiac magnetic resonance (CMR) parameters were evaluated. A composite of major adverse cardiac and cerebrovascular events was assessed.
RESULTS: Genetic variants were detected in 55 of 89 subjects. Pathogenic variants or likely pathogenic variants were identified in 27 of HCM patients in MYBPC3, TNNI3, MYH7, and MYL7. Variants of uncertain significance were identified in 28 patients. There were significant differences in the presence of non-sustained ventricular tachycardia (p = 0.030) and myocardial fibrosis on CMR (p = 0.029) in the detected compared to the not-detected groups. Event-free survival was superior in the not-detected group (p = 0.006).
CONCLUSION: Genetic variants in patients with HCM are relatively common and are associated with adverse clinical events and myocardial fibrosis on CMR. Genotypic analysis may add important information to clinical variables in the assessment of long-term risk for HCM patients.

Entities:  

Keywords:  genotype; hypertrophic cardiomyopathy; phenotype; sarcomeric

Year:  2020        PMID: 32492895     DOI: 10.3390/jcm9061671

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  4 in total

Review 1.  Fibrosis: from mechanisms to medicines.

Authors:  Neil C Henderson; Florian Rieder; Thomas A Wynn
Journal:  Nature       Date:  2020-11-25       Impact factor: 49.962

2.  Effect of sarcomere and mitochondria-related mutations on myocardial fibrosis in patients with hypertrophic cardiomyopathy.

Authors:  Hyemoon Chung; Yoonjung Kim; Chul-Hwan Park; Jong-Youn Kim; Pil-Ki Min; Young Won Yoon; Tae Hoon Kim; Byoung Kwon Lee; Bum-Kee Hong; Se-Joong Rim; Hyuck Moon Kwon; Kyung-A Lee; Eui-Young Choi
Journal:  J Cardiovasc Magn Reson       Date:  2021-03-04       Impact factor: 5.364

Review 3.  Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin.

Authors:  Lei Qin; Nian Liu; Chao-le-Meng Bao; Da-Zhi Yang; Gui-Xing Ma; Wei-Hong Yi; Guo-Zhi Xiao; Hui-Ling Cao
Journal:  Acta Pharmacol Sin       Date:  2022-07-27       Impact factor: 7.169

4.  Phenotypic Diversity of Cardiomyopathy Caused by an MYBPC3 Frameshift Mutation in a Korean Family: A Case Report.

Authors:  Joonhong Park; Jong-Min Lee; Jung Sun Cho
Journal:  Medicina (Kaunas)       Date:  2021-03-18       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.